FDA Logo links to FDA home page
Center for Biologics Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Biologics Evaluation and Research
 HHS Logo links to Department of Health and Human Services website

FDA Home Page | CBER A-Z Index | CBER Search | Contact CBER | CBER Home Page

horizontal rule
CBER links to product areas Blood Vaccines Cellular/Gene Therapy Tissue Devices
CBER links Products Industry Healthcare Reading Room Meetings What's New
horizontal rule

Product Approval Information - Licensing Action

horizontal rule

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448

January 31, 2002

Our STN: BL 103821/5020

Lallan Giri, Ph.D.
BioPort Corporation
3500 N. Martin Luther King Jr. Blvd.
Lansing, MI 48906

Dear Dr. Giri:

Your request to supplement your biologics license application to include Hollister-Stier Laboratories LLC, Spokane, Washington, as a contract manufacturer for the filling of Anthrax Vaccine Adsorbed (AVA) has been approved.

Under this approval, lots of AVA filled at Hollister-Stier Laboratories LLC shall have an expiration dating period of 18 months from the date of manufacture when stored at 2-8 °C. Any requests to extend the dating period beyond 18 months will require the submission of supporting data as a supplement to your biologics license application for review and approval.

We acknowledge your written commitments, as stated in your letter of January 17, 2002, to provide the following additional information post-approval:

  1. Real time stability data on final containers for the consistency lots, FAV063, FAV064 and FAV065, will be accumulated at the following intervals: 6, 9, 12, and 18 months, and these stability data will be provided to CBER as they become available.

  2. BioPort has committed to place a minimum of two filled lots of AVA on stability each year.

  3. To perform a suitable extraction study for the West Stoppers using the diluent of the Anthrax Vaccine Adsorbed. The study will be completed by July 2002 and the results submitted to CBER in the next annual report.

The information contained in the above-referenced supplement will be included in your biologics license application file.

Sincerely yours,

--- signature ---

Steven A. Masiello
Director
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research

 

 
horizontal rule